Hepatitis B “Functional Cure” Nears Phase 3 Threshold as GSK Nucleic Acid Drug Reaches Regulatory Gate
Bepirovirsen kept some chronic hepatitis B patients in a state of hepatitis B surface antigen loss in two late-stage trials, opening a narrow path in a treatment landscape long limited to viral suppression; but response rates of just over 10% to about 20% also show this is not the final answer.